Background Platelet Rich Plasma-Platelet concentrate (PRP-PC), Buffy Coat poor-platelet concentrate (BCPC), and Apheresis -PC were prepared and their therapeutic effi cacy were assessed in thrombocytopenic patients.
Introduction
Platelet transfusions are the primary therapy for thrombocytopenia due to various causes. Thrombocytopenia may be due to qualitative defect, i.e. defect in platelet function or quantitative defect, i.e. decreased platelet count which can be seen in various hemato-oncological patients either due to primary disease or chemotherapy.
The basic principle behind preparation of components from whole blood is that, each component has its specifi c gravity and by applying centrifugation, each component is separated and removed, thus allowing the transfusion of desired component according to the need of the patient.
The recommended shelf life of platelet concentrates in presently available platelet storage bag is 5 days at 22±2°C with continuous agitation. The platelets undergo various storage changes starting from collection, processing to storage and the underlying conditions within the patients, which may affect the therapeutic benefi t to the recipient [1] .
The in vivo platelet quality can be assessed by using corrected count increment (CCI) and percentage recovery (PR) at 1 hour and 20 hours post transfusion which accesses the functional platelets in circulation after transfusion. If the CCI at 1 hr and 20 hour is <7500 platelets/ μL/m 2 and < 4500 platelet/μL/m 2 and PR at 1 hour and 20 hour <30% and <20% respectively on two consecutive occasions it indicates platelet transfusion refractoriness [2] .
In this study we have analyzed the quality of different platelet concentrates prepared by different methods as per the quality norms recommended and assessed the therapeutic benefi ts of each of these platelet concentrates in thrombocytopenic patients.
Material and methods
This study was conducted during the period from January-2003 to December-2003 in the departments of Transfusion Medicine, Hematology and lab. and Internal Medicine of the institute, after obtaining clearance from the ethics committee of the institute.
During this period, total number of 44,069 whole blood units were collected, and 7,167 random donor platelets [PRP-PC-3,081(6.9%) and BC-PC-810(1.8%)] were prepared. Whole blood was collected in 450-ml bag containing 63 ml of CPDA1 anticoagulant, kept at room temperature (20-24°C) and PRP-PC was prepared within 6-8 hours of collection.
Single donor platelets were prepared from ninety-eight (98) donors by continuous fl ow, double venous access, automated cell separator -CS3000 ® plus, Baxter, Fenwal division, Deerfi eld, 14 60015, USA. The study group Patients with mainly hematological disorders with severe thrombocytopenia (i.e., platelet count < 20000/μl), who required prophylactic or therapeutic platelet transfusion were subjects of the study. Twenty patients each were evaluated for therapeutic effi cacy of platelet rich plasma-platelet concentrate (PRP-PC), buffy coat poor-platelet concentrate (BC-PC) and apheresis PC. Exclusion criteria Patients with high-grade fever (≥102°F), splenomegaly (moderate to massive), idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP) were excluded, as these conditions are known to be associated with unduly increased utilization of platelets. Sample collection Two to three ml of sample from platelet concentrates either SDP or RDP was collected aseptically in plain vial prior to the transfusion to the patients. Two to three ml of patient's blood was collected in EDTA at three different times, fi rst sample 1-2 hours prior to the transfusion after a requisition was received for platelet transfusion and rest of the two samples were collected at 1 hour and 20 hours post-transfusion respectively. Platelet counting was done by automated cell counter (MS 4 Melet Schloesing, laboratories, France) .
In vivo effi cacy of transfused platelets was assessed by calculating the corrected count increment (CCI) and percentage recovery (PR) at 1 hour and 20 hours of transfusion respectively. Statistical analysis All data were expressed as mean±SD. We performed statistical comparison by using't'-test for multiple groups. A probability of p<0.05 (two sided) was used to reject null hypothesis. 
